| Positive charge of “sticky” peptides and proteins impedes release from negatively charged PLGA matrices SC Balmert, AC Zmolek, AJ Glowacki, TD Knab, SN Rothstein, ... Journal of materials chemistry B 3 (23), 4723-4734, 2015 | 41 | 2015 |
| A quantitative modeling and simulation framework to support candidate and dose selection of anti‐SARS‐CoV‐2 monoclonal antibodies to advance bamlanivimab into a first‐in‐human … E Chigutsa, E Jordie, M Riggs, A Nirula, A Elmokadem, T Knab, JY Chien Clinical Pharmacology & Therapeutics 111 (3), 595-604, 2022 | 19 | 2022 |
| A systems approach to modeling drug release from polymer microspheres to accelerate in vitro to in vivo translation TD Knab, SR Little, RS Parker Journal of controlled release 211, 74-84, 2015 | 19 | 2015 |
| Zone model predictive control and moving horizon estimation for the regulation of blood glucose in critical care patients TD Knab, G Clermont, RS Parker IFAC-PapersOnLine 48 (8), 1002-1007, 2015 | 17 | 2015 |
| A “virtual patient” cohort and mathematical model of glucose dynamics in critical care TD Knab, G Clermont, RS Parker IFAC-PapersOnLine 49 (26), 1-7, 2016 | 11 | 2016 |
| Modeling glucose and subcutaneous insulin dynamics in critical care A Pritchard-Bell, G Clermont, TD Knab, J Maalouf, M Vilkhovoy, RS Parker Control Engineering Practice 58, 268-275, 2017 | 9 | 2017 |
| CD19 expression by IHC alone is not a predictor of response to loncastuximab tesirine: results from the LOTIS-2 clinical trial and quantitative systems pharmacology modeling PF Caimi, M Hamadani, C Carlo-Stella, M Nickaeen, E Jordie, K Utsey, ... Blood 140 (Supplement 1), 9548-9550, 2022 | 6 | 2022 |
| Bayesian pbpk modeling using r/stan/torsten and julia/sciml/turing. jl A Elmokadem, Y Zhang, T Knab, E Jordie, WR Gillespie CPT: Pharmacometrics & Systems Pharmacology 12 (3), 300-310, 2023 | 5 | 2023 |
| Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data JS Barrett, M Cala Pane, T Knab, W Roddy, J Beusmans, E Jordie, ... Frontiers in Pharmacology 13, 988974, 2022 | 3 | 2022 |
| Toxicity-centric cancer chemotherapy treatment design JT Liparulo, TD Knab, RS Parker IFAC-PapersOnLine 53 (2), 16353-16358, 2020 | 3 | 2020 |
| The impact of a responsive endogenous pancreas in critical care glucose control RS Parker, TD Knab, G Clermont 2018 Annual American Control Conference (ACC), 3595-3601, 2018 | 3 | 2018 |
| Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL Y Li, AK Wilkins, T Knab, JP Boni Cancer Research 84 (6_Supplement), 875-875, 2024 | | 2024 |
| In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine PF Caimi, M Hamadani, C Carlo‐Stella, M Nickaeen, E Jordie, K Utsey, ... Ejhaem 5 (1), 76-83, 2024 | | 2024 |
| Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy EB Jordie, L Gibiansky, T Knab, A Lemenuel‐Diot, P Ravva, E Zwanziger, ... British Journal of Clinical Pharmacology 88 (3), 1189-1201, 2022 | | 2022 |
| Model-Based Closed-Loop Glucose Control in Critical Illness TD Knab University of Pittsburgh, 2017 | | 2017 |
| AnOpenSourcePackageSuiteinJuliatoFacilitateQSPModelingandSimulation T Knab, E Jordie, M Riggs, A Elmokadem | | |
| Exploring the Influence of Bispecific Antibody Mechanisms on In Vitro Dose Response: Insights from an Open-Science Quantitative Systems Pharmacology Model in Julia K Utsey, E Jordie, T Knab, E Sobie, AK Wilkins | | |
| A multi-organ integrated QSP model for hematopoietic stem cell differentiation to predict the immune cell reconstitution in ex-vivo gene therapy Y Li, E Jordie, T Knab | | |
| Deep QSP Modeling: Leveraging Machine Learning for QSP Model Development and Evaluation A Elmokadem, T Knab, E Jordie, Y Li | | |
| A Clinical Quantitative Systems Pharmacology Framework Describing Loncastuximab Tesirine Distribution and the Exploration of Patient Outcomes From the LOTIS-2 Clinical Trial in … K Utsey, E Jordie, T Knab, K Wilkins, M Nickaeen, S Pantano, ... | | |
